Localized delivery of nanomedicine and antibodies for combating COVID-19.
10.1016/j.apsb.2022.09.011
- Author:
Bin TU
1
;
Yanrong GAO
1
;
Xinran AN
1
;
Huiyuan WANG
1
;
Yongzhuo HUANG
1
Author Information
1. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- Publication Type:Review
- Keywords:
Antibody;
COVID-19;
Intranasal delivery;
Nanomedicine;
Orally-inhaled delivery;
SARS-CoV-2
- From:
Acta Pharmaceutica Sinica B
2023;13(5):1828-1846
- CountryChina
- Language:English
-
Abstract:
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been a major health burden in the world. So far, many strategies have been investigated to control the spread of COVID-19, including social distancing, disinfection protocols, vaccines, and antiviral treatments. Despite the significant achievement, due to the constantly emerging new variants, COVID-19 is still a great challenge to the global healthcare system. It is an urgent demand for the development of new therapeutics and technologies for containing the wild spread of SARS-CoV-2. Inhaled administration is useful for the treatment of lung and respiratory diseases, and enables the drugs to reach the site of action directly with benefits of decreased dose, improved safety, and enhanced patient compliance. Nanotechnology has been extensively applied in the prevention and treatment of COVID-19. In this review, the inhaled nanomedicines and antibodies, as well as intranasal nanodrugs, for the prevention and treatment of COVID-19 are summarized.
